Human hepatic stellate cell isolation and characterization


The hepatic stellate cells (HSCs) localize at the space of Disse in the liver and have multiple functions. They are identified as the major contributor to hepatic fibrosis. Significant understanding of HSCs has been achieved using rodent models and isolated murine HSCs; as well as investigating human liver tissues and human HSCs. There is growing interest and need of translating rodent study findings to human HSCs and human liver diseases. However, species-related differences impose challenges on the translational research. In this review, we focus on the current information on human HSCs isolation methods, human HSCs markers, and established human HSC cell lines.


The hepatic stellate cells (also referred to as Ito cell, fat-storing cell, lipocyte, perisinusoidal cell, parasinusoidal cell) are one of the key nonparenchymal components in the sinusoid compartment with multiple functions in the liver. HSCs were first described and named “Sternzellen” in 1876 by Kupffer [1] using a gold-chloride impregnation technique. Later Toshio Ito [2] and Bronfenmajer [3] observed perisinusoidal cells containing lipid droplets in human livers. Wake [4] identified that “Sternzellen” were the same cells as the vitamin A-storing cells in the liver. In 1995, the international community of investigators recommended the nomenclature of hepatic stellate cell (HSC) [5]. The embryologic origin of HSCs remains unresolved. Based on expression markers, potential origins of HSCs include endoderm (cytokeratins) [6], or the septum transversum mesenchyme (Foxf1, vimentin) [7], or neural crest (GFAP, synaptophysin, N-CAM) [8] and P75 [9]). However, the neural crest origin has been challenged [10]. Recent studies utilizing cell-fate mapping in mice have suggested that HSCs may originate from septum transversum [11].

Under physiological conditions, HSCs reside in the space of Disse exhibiting a quiescent phenotype (qHSCs), and their main function is storing vitamin A in lipid droplets [12, 13]. In response to injury, qHSCs decrease vitamin A storage and peroxisome proliferator-activated receptor gamma (PPARϒ) expression, and activate into myofibroblasts (aHSCs), which are characterized by increased proliferation and high contractility with expression of pericellular matrix proteins (α-smooth muscle actin (α-SMA), vimentin), and secretion of abundant extracellular matrix proteins (fibronectin, collagen type I and III) [14,15,16,17]. HSCs release inflammatory, proliferative, and fibrogenic cytokines such as IL-6, PDGF, and TGFβ, through direct contact with their neighboring cells [18]. It is reported that HSCs can also function as regulatory bystander and contribute to liver-induced tolerance [19]. HSCs also contribute to liver regeneration [20], and potentially mediate sinusoidal blood flow via contraction and regulate microvascular structure and function in liver [21].

The development of methodologies and techniques for isolating and culturing primary HSCs has provided a platform for great achievements in understanding this cell’s unique and pleiotropic functions in liver pathophysiology. Knook et al., using density centrifugation and centrifugal elutriation, first established the isolation of HSCs from rat liver [22]. Subsequently, the first human HSC isolation and characterization was reported by Friedman from normal liver [23]. With the development of techniques for HSC isolation, cultivation and characterization, dramatic achievement has been made in exploring the physiological and pathological functions of HSCs. Mouse models have been a very valuable tool in characterizing cellular gene activation and protein-expression profiles as well as elucidating the signaling pathways involved. Especially, mouse models utilizing HSC specific markers has greatly advanced our understanding of the function of HSCs [24,25,26,27]. Meanwhile, significant advancement has been made in human liver pathology studies as well as in vitro studies using isolated primary human HSCs, for example, to study their reverting capacity and function in retinoid metabolism [28,29,30,31,32,33]. There is increasing interest in translating research from mouse models and mouse HSCs to human HSCs and human disease. In this review we will examine the current information on human HSCs, including the methodologies for HSC isolation, primary cultures of human HSCs, human liver tissues, as well as established human HSC cell lines.

Human HSC isolation methods

An efficient method of HSC isolation and clear characterization of human HSCs is undoubtedly critical for a deep understanding of its role in human liver physiology and liver diseases. Two main methods for isolating HSCs from human liver have been described so far, one is to grow smooth muscle-like cells from liver tissue explants, and the other is using density gradient centrifugation similar to the isolation of HSCs in rodents [22, 34].

Liver tissue explants

Culture and characterization of myofibroblasts grown from human liver explants of normal and fibrotic livers were reported about 40 years ago [35,36,37]. Tissue fragments were attached to plastic substratum. The outgrowth of cells with myofibroblast characteristics became detectable after 10–15 days, and the myofibroblastic cells were recovered and passaged by trypsinization after 3–4 weeks culturing from the explants of liver sections [38]. Generally, studies were carried out on homogeneous cultures of “smooth muscle cells” subcultured between three and ten passages, without noticeable phenotypic alterations and significant result variation from various passages [36, 38,39,40,41].

The HSCs/myofibroblasts grown from explants of human liver provide a useful research model to study human fibrogenesis. The cells are positive for desmin and smooth muscle α-actin, and demonstrate features typical of myofibroblasts, such as abundant rough endoplasmic reticulum (ER) and bundles of microfilaments under transmission electron microscopy. Typical lipid droplets were not detectable, since these cells were kept in culture long enough to be considered as fully ‘activated’ [38]. They express collagen types I, III, IV, and V; and also laminin B1 chain, fibronectin, matrix-metalloproteinase-2 (MMP-2) [37, 39], and fibroblast activation protein (FAP) [42].

Similar to the outgrowth from liver slice cultures, some studies have isolated human HSC-like myofibroblasts through culture purification from mixed crude liver cell populations, obtained from perfused normal human livers. Stellate-cell growth in mixed cultures revealed that more than 80% displayed desmin and α-SMA expression, and also express interstitial collagens type I and III. Using this cell culture system, researchers demonstrated that retinoic acid suppressed the response of myofibroblasts to PDGF, while this suppressive effect did not alter PDGFRα or β abundance or activation [43].

The limitations of this approach include the potential heterogeneity of the cells in culture. Under these culture conditions, two cell types, which resemble smooth muscle cells and vascular endothelium, grew from the liver tissue [37], while epithelial cells were no longer present in these subcultures [36, 37]. Moreover, using this culture method, early events of HSC activation cannot be traced and investigated, since it takes weeks for the cells to grow out of the liver tissue and onto plastic surface.

Isolation of human HSCs using density gradient centrifugation

Friedman [23] first successfully isolated, cultured, and characterized human HSCs (lipocytes) from normal human livers. Isolation of human HSC (fat-storing cells) was also reported in other studies using density gradient centrifugation method [31, 44, 45]. In general, researchers isolated human HSCs from wedge sections of human liver unsuitable for transplantation within 48 h. Sections of donor liver were isolated by catheter perfusion [23], or finely minced [44, 45], and digested using pronase and collagenase, followed by density gradient centrifugation using Larex (Stractan) or other gradient medium to remove other non-parenchymal cells. HSCs isolated with this method were reported to be highly viable and with purity of ~ 90% [23, 44]. In some studies, HSCs isolated from density gradient centrifugation were further enriched and purified by centrifugal elutriation [46].

The isolated hHSCs display vitamin A autofluorescence with numerous lipid droplets in the perinuclear zone [47]. Retinoid droplets were maintained for 9 days on uncoated plastic, with subsequent loss of vitamin A droplets and progression to a fibroblastic morphology with expression of matrix constituents including α-SMA on day 14 in culture on uncoated plastic. Conversely, cells cultured on basement membrane-like gel remained clustered and retained vitamin A fluorescence. Transmission EM demonstrated abundant retinoid droplets, prominent rough ER, and prominent microfilaments. Cytoskeletal and matrix protein expression investigation reported that desmin expression was negative in hHSCs within 2–3 day culture, and only seen in cells in longer-term culture (> 7 days) with polyclonal but not monoclonal primary antibody. Vimentin, collagens I, III, IV, FN, and laminin were identified [23, 47]. Researchers found that these hHSCs respond to vasoconstrictors such as thrombin, angiotensin-II, and endothelin-1, suggesting their role in regulating sinusoidal blood flow [44]. The cultured hHSCs produced monocyte chemotactic protein-1 (MCP-1) [45], and responded to TGFβ1 with increased PDGFRβ [48]. It has been demonstrated that density gradient isolated human HSCs can be reverted to a quiescent-like phenotypes through synergistic action of epidermal growth factor (EGF), fibroblasts growth factor 2 (FGF2), dietary fatty acids (oleic acid, palmitic acid) and retinol, as demonstrated by the abundant presence of retinyl ester-positive intra-cytoplasmic lipid droplets, and low expression levels of activation markers [31].

Density gradient separation remains the most widely used approach for HSC isolation, but this method targets the buoyancy of vitamin A-rich HSCs. This could result in inefficiency on isolating ‘activated’ HSCs. It has been demonstrated that upon liver injury, large number of HSCs were retrieved from higher density gradient layers in rat [34].

NPC stepwise-separation method

Recently, a detailed protocol for human liver hepatocytes, NPC (non-parenchymal) fractions including Kupffer cells, liver endothelial cells, and HSCs was reported [49, 50]. In this method, NPCs were purified by Percoll density gradient centrifugation. Kupffer cells (KCs), liver endothelial cells (LECs) and hepatic stellate cells (HSCs) were separated using specific adherence properties and magnetic activated cell sorting (MACS). Specifically, KCs were isolated through adherence separation step since they adhere on cell culture plastics within a short period of time; then LECs were isolated from HSCs using MACS with CD31 micro beads; unlabeled HSCs were collected as the pass-through of the separation column during the MACS procedure. Using this method, HSCs with purity of ~ 93% can be achieved, which were GFAP positive.

Fluorescent-activated cell sorting

Using the HSC characteristic of retinoid droplet storage, a pure HSC population was obtained by sorting of HSC based on endogenous vitamin A fluorescence with high side scatter (SSC) of incident light [51, 52]. The disadvantage of this method is the lower yield, higher cost, and requires a fluorescence-activated cell sorting (FACS). This method, however, remains valuable for obtaining pure hepatic stellate cells. Importantly, in human HSC isolation, a major concern is hepatocyte contamination, especially from a steatotic liver, in which contaminated hepatocytes also generate strong autofluorescence, making the sorting purification of HSCs challenging.

Liver slice culture

Liver slice culture offers some unique advantages and has been used in various studies. The precision-cut liver slice model maintains cell–cell and cell–matrix interactions and therefore preserves the native physiologic milieu of resident liver cells [53] (Emilia Gore et al. 2017 keystone symposium) [54]. It was reported that slices of adult human [55] liver were cultured at the air–fluid interface for up to 28 days, with stellate cells positive for α-SMA and reticulin [53]. Using this method, the research demonstrated distinguished expression pattern of α-SMA, PDGFRβ and Thy-1 in normal, cirrhotic and cholestatic livers [56].

Co-culture method

A recent study reported a 3D organotypic co-cultivation system for hepatocyte and non-parenchymal cells (NPCs). Using long-term cell co-culture, density gradient centrifugation and MACS, high purity and good separation of endothelial cells (ECs), Kupffer cells (KCs), dendritic cells (DCs), invariant natural killer T (iNKT) cells were obtained and then added back in a biogel into a 3D culture. In this system, HSCs were identified by desmin and GFAP expression, and most of the HSCs were α-SMA positive [57].

Human HSC markers (Table 1, Fig. 1)

Rodent studies have identified specific markers for HSCs. The most prominent proteins identified in rodent HSCs include desmin, GFAP, and α-SMA (when activated) [58, 59]. However, rodents and human HSCs not only show dramatic morphological discrepancy, but also the protein expression profile of human HSCs is quite different from mouse HSCs. In particular, immunostaining does not identify desmin or GFAP-positive cells in quiescent human HSCs [60, 61]. Therefore, it is important to identify specific markers for human HSCs.

Table 1 Mouse HSC and human HSC markers
Fig. 1

Immunofluorescence staining for GFAP, desmin, and α-SMA of primary mouse HSCs and primary human HSCs

Morphologic identification

Transmission electron microscopy remains the gold standard for identification of HSCs based on location, cytoplasmic processes, lipid droplet content, rough endoplasmic reticulum, and bundles of microfilament [23, 62]. Morphologic features by light microscopy include presence of lipid droplets and stellate (star) shape of the cells. The most characteristic morphologic feature of HSCs in a normal liver is their storage of vitamin A in the form of cytoplasmic retinoid droplets [4]. These cytoplasmic lipid droplets are readily identifiable in live biopsies [63, 64]. Loss of retinoid is a prominent feature accompanying stellate cell activation. However, it was reported that in patients with normal liver histology, only 75% of the perisinusoidal cells contain lipids [65].

Cytoskeletal proteins


Yokoi et al. discovered desmin in rat HSCs [58]. Since then, desmin has been widely used as a ‘gold standard’ for identifying HSCs in rodent liver. However, data of desmin on HSC studies obtained in human subjects have been contradictory [38, 64, 66, 67]. Some studies have shown that perisinusoidal liver cells in normal adult liver tissue are devoid of desmin expression [66, 68], and desmin immunostain has been reported to be negative in fibrotic human livers [67, 69, 70]. While others have suggested positive desmin immunoreactivity in normal [38] or cirrhotic human livers [66]. As well, in isolated human HSCs, the results are not consistent. Positive immunostaining for desmin has been observed in primary isolated human HSCs in some studies [23, 31, 38], while negative immunoreactivity for desmin was reported in others [61, 71].

Alpha-SMA (α-SMA)

This is used as a reliable marker of activated and myofibroblastic HSCs. This cytoskeletal protein is absent from other resident liver cells except portal myofibroblasts and vascular smooth muscle cells [42, 66]. In normal and pathological adult human livers, positive immunostaining of α-SMA was identified in fat-droplet-containing HSCs, and increased cell number and intensity of the staining signal was observed in the specimens with chronic liver disease [66, 68, 72]. Some studies reported no α-SMA immunoreactivity detected in normal human liver [42, 73]. Expression of vimentin, vinculin, procollagens I, III, collagen IV, V, laminin, and fibronectin are identified in human HSCs [23, 39, 64, 70].

Neural markers

Stellate cells are directly adjacent to nerve endings [74], and studies have identified neurotrophin receptors [75] with functional studies confirming neurohumoral responsiveness of HSCs [18, 76, 77].

GFAP (glial fibrillary acidic protein)

Rodent HSCs express GFAP [59, 61]. In normal human liver tissue, GFAP immunoreactivity was absent [42]. However, a small subpopulation of periportal cells was reported as GFAP-positive in normal human liver in a different study [78]. In cirrhotic livers, GFAP was detected in focal clusters of cells in the periseptal regions of the regenerative nodules [42]. Positive GFAP staining was also identified in HSCs in fibrotic/cirrhotic livers [69]. Isolated human HSCs were reported as GFAP positive in some studies [49, 50, 61, 71], while no GFAP immunoreactivity was detected in isolated HSCs from cirrhotic liver explants [42].

NGFRp75 (surface marker) (nerve growth factor receptor p75)

Studies showed that human HSCs express the low-affinity nerve growth factor receptor p75, which was detected in perisinusoidal cells in normal donor liver sections. Also in fibrotic and cirrhotic livers, intense staining of p75 was observed immunolocalized with α-SMA-positive HSCs, and no p75 expression was observed in hepatocytes [69, 75, 79]. Quiescent (freshly isolated) HSCs did not express p75; its expression first became detectable in activated HSC after 7 days of culture in rat, and after 14 days of culture by Western-blot analysis in activated human HSCs [79]. P75 immunostain has shown inconsistent results in several human HSC cultures [61].

Trk-C (surface marker) (NTRK3, neurotrophic receptor tyrosine kinase receptor 3)

Notably, Trk-C is expressed in both rodent and human HSCs in normal and varying pathologic conditions [69, 75]. Vascular smooth muscle cells also express Trk-C [80]. However, lost expression of Trk-C was reported in cultured human HSCs [61].

N-CAM (surface marker) (neural cell adhesion molecule)

N-CAM was found to be present in periportal and intermediate-zonal human HSCs. Such intralobular heterogeneity of N-CAM expression might be related to the different maturational stages of the HSCs [81]. N-CAM-positive HSCs were also demonstrated in cirrhotic human livers co-localized with α-SMA [69]. N-CAM immunostain has shown inconsistent results in cultured human HSCs [31, 61].

NT-3 (neurotrophin-3)

NT-3 was detected in human HSCs in normal or various pathologic conditions; for example, positive immunostaining for NT-3 was observed in HSCs lining the sinusoids in human liver with alcoholic cirrhosis [69]. Weak immunoreactivity of NT-3 was also detected in hepatocytes in cryosections of human liver [75]. Positive NT-3 staining was observed in isolated human HSCs [61].

Retinol processing proteins

CRBP-1 (cellular retinol binding protein-1)

CRBP-1 is a carrier protein of intracellular retinol. Diffuse light staining by immunohistochemistry for CRBP-1 was seen in the cytoplasm of hepatocytes, while much more intense positive signal for HSCs were observed in rat [82]. In formalin-fixed paraffin embedded human live tissues, positive CRBP-1 staining was observed in lobular HSCs without reacting with smooth muscle cells and cholangiocyte positivity [70]. CRBP-1 was downregulated in human livers with advanced fibrosis, presumably due to a loss of vitamin A [64].

CYGB/STAP (cytoglobin/stellate cell activation-associated protein)

Cytoglobin was discovered by a proteome analysis of rat HSCs [83]. In the rat liver, Cygb is expressed in the quiescent HSCs and is increased when these cells were activated in fibrotic liver tissues. In normal human liver, CYGB-positive cells have similar distribution as in normal rat liver; however its expression is not increased around inflammatory lesions, which is not consistent with the observation in the inflammatory regions of rat liver [84]. Other hepatic constituent cells in liver lobules such as Kupffer cells, endothelial cells, hepatocytes, and bile-duct epithelial cells are negative for Cygb immunostaining [85]. Quiescent stellate cells, but not portal myofibroblasts, express both CYGB and CRBP-1 in normal human liver. In fibrotic and cirrhotic livers, it was shown that the distribution of CYGB was mutually exclusive with the distribution of Thy-1, and FBLN2 [64]. Thy-1+ cells were located within the periportal tract in normal human liver [86], and its expression was observed in the fibrotic septa of cirrhotic liver [56]. Co-staining of Thy-1 and CD248 was detected in isolated human hepatic stellate cells [87]. It has been reported that cytoglobin expression is correlated with a more quiescent phenotype of HSCs and is regulated by extracellular matrix proteins dependent on FAK signaling in rat HSC-T6 cell line [88].

LRAT (lecithin retinol acyltransferase)

This enzyme is responsible for all retinyl ester synthesis within the liver and plays an indispensable role in the formation of HSC lipid droplets [63, 89], and was identified as a specific marker for HSCs [24]. LRAT-positive staining was demonstrated in the space of Disse of normal human liver, and was suggested to be recognized as a quiescent HSC marker in human tissue [73]. LRAT+/CRBP-1+ HSCs were demonstrated to contribute to portal fibrosis in human liver specimens in viral hepatitis [29].

Other membrane proteins and markers

FAP: (fibroblast activation protein)

FAP is a cell surface-bound protease of the prolyl oligopeptidase gene family expressed at sites of tissue remodeling. FAP mRNA and immunoreactivity were detected in cirrhotic, but not normal human livers. FAP colocalized with α-SMA in vivo and in isolated HSCs in vitro [42]. It was suggested that FAP expression was related to the severity of liver fibrosis [90].

PDGFRβ (plate-derived growth factor receptor β)

The PDGF receptor was the first membrane receptor identified on HSCs. Human stellate cells contain high levels of both PDGF α- and β-receptors, whereas rat cells contain predominantly the PDGF β-receptor [38, 43, 91,92,93]. PDGFRβ expression was identified in both quiescent and activated HSCs in rodents [91, 94, 95]. In cirrhotic human liver, PDGFRβ expression was markedly increased [28]. Using precision-cut liver slices, PDGFRβ expression was observed in fibrotic septa of cirrhotic liver before culture and was maintained after culture [56]. PDGFRβ mRNA was also detected in hHSCs grown from human liver tissue explants [38], and could be used as an activated HSC marker [84].

B7-H1 (PDL1 or programmed death ligand-1)

HSC expresses the co-stimulatory molecule on activated but not resting HSCs [96].

SYN (synaptophysin)

This neural marker was present in perisinusoidal HSCs in human normal liver biopsies, and increased in pathological conditions such as chronic biliary disease and chronic hepatitis C [69, 97, 98].

ABCRYS (alpha B-crystallin)

In normal and cirrhotic human livers, perisinusoidally located, stellate-shaped cells were stained positive for ABCRYS [61, 69, 71]. Cultured human HSCs, isolated from normal donor livers, were also shown positive ABCRYS immunoreactivity [71].

Human hepatic stellate cell lines (Table 2)

There are obvious disadvantages in obtaining and usage of primary HSCs, particularly primary human HSCs, such as the heterogeneity of isolated cell populations and cellular characteristics, limited supply, considerable variations of cell preparation in different laboratories, as well as the isolation equipment and techniques requirements. Immortalized HSC lines were established and have been used in a wide range of research. These immortalized cell lines provide unlimited resource supply, homogeneity, and are suitable for genetic manipulation studies. They recapitulate many activated HSC features, and can serve as a useful tool for mechanistic investigation of HSC function in hepatic fibrosis and liver pathophysiological processes. The immortalized HSC lines currently in use have been generated from primary HSC through spontaneous immortalization during long-term culture, or by transformation with the simian virus 40 large T-antigen (SV40T), or ectopic expression of human telomerase reverse transcriptase (TERT). Notably, none of the published cell lines are reported to be tumorigenic. Considering these cells are ‘genetically modified’, careful evaluation of the reported studies is always warranted [18, 99].

Table 2 Characteristics of human hepatic stellate cell lines

The LI90 line

The LI90 cell line is the first reported human HSC line derived from a human hepatic epithelioid hemangioendothelioma [100]. LI90 cells express α-SMA, vimentin, collagen types I, III, IV, V, and VI, fibronectin, laminin, and MMPs [101]. They are desmin negative and do not express endothelial or monocyte/macrophage-lineage markers. When exposed to medium supplemented with retinoids, LI90 cells accumulate vitamin A-containing lipid droplets [100].

TWNT-1 and TWNT-4 cell line

The TWNT-1 [102, 103] and TWNT-4 [104] cell lines were derived from retrovirally induced human telomerase reverse transcriptase into the LI90 cell line, since the parental LI90 cells were observed to enter replicative senescence. TWNT-1 cells synthesized Col1α1, HGF, and could uptake acetylated low-density lipoproteins, and TWNT-4 expressed PDGFRβ, α-SMA, Col1α1.

hTERT HSC line

Schnabl et al. described a cell line immortalized by ectopic expression of the human telomerase reverse transcriptase (hTERT) gene in primary HSCs isolated from surgical specimens of normal liver. Extensive characterization of gene and protein expression revealed that this cell line has a similar gene expression profile as the activated human HSC including PDGFRα and β, GFAP, collagen1a1, and α-SMA [105, 106]. Importantly, this cell line undergoes transition to quiescent status when cultured in a basement membrane-like matrix.

LX-1 and LX-2

LX-1 and LX-2 are the most utilized human HSC lines. LX-1 was generated by transformation with SV40 T antigen, and LX-2 was obtained through spontaneous immortalization in low serum culture [107]. Both cell lines express α-SMA, vimentin, GFAP, PDGFRβ, discoidin domain receptor 2 (DDR2), and leptin receptor OB-RL. Both cell lines also express matrix remodeling factors, including MMP-2, TIMP-1, TIMP-2, MT1-MMP, and multiple neuronal genes. Both cell lines express mRNA for procollagen 1α1 and HSP47, and they retain key features of HSC such as accumulating retinol and converting it to retinyl ester [26, 108,109,110].


This cell line was established by immortalizing human liver myofibroblasts, obtained from explants of human liver and transfected with a plasmid containing the coding sequencing of polyoma virus large T antigen expressed under the control of the early promoter of cytomegalovirus (CMV) [111]. GREX-X cells stain positive for α-SMA and vimentin, and express collagen types I, IV, V, and VI, fibronectin, and laminin, and secrete MMP-2. Importantly, GREF-X cells are able to take up and esterify retinol, and respond to TGFβ1 [111].


Recently, a human HSC line was established by immortalizing the primary human HSCs isolated from surgical specimen of adult liver donors using the simian virus 40 large T antigen (SV40LT) for application in a co-culture system with immortalized human hepatocytes in vitro [112]. HSC-Li cells were longitudinally spindle-like and contained fat droplets in their cytoplasm as observed under electron microscopy. It expresses mRNAs for hepatocyte growth factor (HGF), VEGF receptor 1 (Flt-1), Col1α1, and Col1α2, and positive for α-SMA, PDGFRβ, and vimentin proteins.

All of these cell lines should be categorized as myofibroblast-like cells since they contain few or no lipid droplets, express α-SMA, and synthesize collagen type I and fibronectin.


In the normal liver, HSCs comprise 5–8% of total rat liver cells [113]. In mouse liver, HSCs comprise a population of 8–10% of total liver cells, but rapidly expand in response to chronic fibrogenic injury corresponding to ~ 15% of total liver cells [114]. Pathogenic mechanisms responsible for development of hepatic fibrosis and liver failure are poorly understood. Newer studies are showing that there might be differences in pathways that are involved in hepatic fibrosis that are etiology dependent. For example, HSCs are identified as a major source of myofibroblasts in hepatotoxic-induced liver fibrosis, such as alcohol or CCl4. Following chronic injury, HSCs activate into myofibroblast-like cells, acquiring contractile, pro-inflammatory, and fibrogenic properties. They have also been shown to inactivate and acquire a quiescent-like phenotype, which might help with regression of liver fibrosis [114, 115]. As well, blockage of certain proteins in HSC activation pathways might prove to have therapeutic implication in human diseases [98, 116,117,118]. Mouse model studies and advanced HSC isolation techniques have contributed to the elucidation of this cell’s functions. However, species-differences are critical to translational research. Protein expression patterns of normal and activated HSCs are not identical among species, which imposes challenges on the translational research, and therefore it is imperative to develop tools and techniques for investigating human HSCs to confirm and extend studies in rodent models.


  1. 1.

    Kv Kupffer. Ueber Sternzellen der Leber. Briefliche Mitteilung an Prof. Waldyer. Arch Mikrosk Anat. 1876;12:353–8.

    Article  Google Scholar 

  2. 2.

    Ito T, Nemoto M. Kupfer’s cells and fat storing cells in the capillary wall of human liver. Okajimas Folia Anat Jpn. 1952;24(4):243–58. Uber die Kupfferschen Sternzellen und die Fettspeicherungszellen (fat storing cells) in der Blutkapillarenwand der memschlichen Leber.

  3. 3.

    Bronfenmajer S, Schaffner F, Popper H. Fat-storing cells (lipocytes) in human liver. Arch Pathol. 1966;82(5):447–53.

    CAS  PubMed  Google Scholar 

  4. 4.

    Wake K. “Sternzellen” in the liver: perisinusoidal cells with special reference to storage of vitamin A. Am J Anat. 1971;132(4):429–62.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Gutierrez-Ruiz MC, Gomez-Quiroz LE. Liver fibrosis: searching for cell model answers. Liver Int. 2007;27(4):434–9.

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Vassy J, Rigaut JP, Briane D, et al. Confocal microscopy immunofluorescence localization of desmin and other intermediate filament proteins in fetal rat livers. Hepatology. 1993;17(2):293–300.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Kalinichenko VV, Bhattacharyya D, Zhou Y, et al. Foxf1 ± mice exhibit defective stellate cell activation and abnormal liver regeneration following CCl4 injury. Hepatology. 2003;37(1):107–17.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Geerts A. On the origin of stellate cells: mesodermal, endodermal or neuro-ectodermal? J Hepatol. 2004;40(2):331–4.

    PubMed  Article  Google Scholar 

  9. 9.

    Kendall TJ, Hennedige S, Aucott RL, et al. p75 Neurotrophin receptor signaling regulates hepatic myofibroblast proliferation and apoptosis in recovery from rodent liver fibrosis. Hepatology. 2009;49(3):901–10 (Epub 2008/12/17).

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Cassiman D, Barlow A, Vander Borght S, et al. Hepatic stellate cells do not derive from the neural crest. J Hepatol. 2006;44(6):1098–104.

    CAS  PubMed  Article  Google Scholar 

  11. 11.

    Asahina K, Zhou B, Pu WT, et al. Septum transversum-derived mesothelium gives rise to hepatic stellate cells and perivascular mesenchymal cells in developing mouse liver. Hepatology. 2011;53(3):983–95.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. 12.

    Kisseleva T, Brenner DA. Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol. 2006;21(Suppl 3):S84–7.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Iwaisako K, Brenner DA, Kisseleva T. What’s new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. J Gastroenterol Hepatol. 2012;27(Suppl 2):65–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209–18.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood). 2008;233(2):109–22 (Epub 2008/01/29).

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Eyden B. The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine. J Cell Mol Med. 2008;12(1):22–37 (Epub 2008/01/10).

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Parola M, Marra F, Pinzani M. Myofibroblast—like cells and liver fibrogenesis: emerging concepts in a rapidly moving scenario. Mol Aspects Med. 2008;29(1–2):58–66 (Epub 2007/11/21).

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88(1):125–72.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Ichikawa S, Mucida D, Tyznik AJ, et al. Hepatic stellate cells function as regulatory bystanders. J Immunol. 2011;186(10):5549–55.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  20. 20.

    Saito Y, Morine Y, Shimada M. Mechanism of impairment on liver regeneration in elderly patients: role of hepatic stellate cell function. Hepatol Res. 2017;47(6):505–13.

    PubMed  Article  Google Scholar 

  21. 21.

    Semela D, Das A, Langer D, et al. Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. Gastroenterology. 2008;135(2):671–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Knook DL, Seffelaar AM, de Leeuw AM. Fat-storing cells of the rat liver. Their isolation and purification. Exp Cell Res. 1982;139(2):468–71.

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Friedman SL, Rockey DC, McGuire RF, et al. Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. Hepatology. 1992;15(2):234–43.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Mederacke I, Hsu CC, Troeger JS, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013;4:2823.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  25. 25.

    Radaeva S, Sun R, Jaruga B, et al. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology. 2006;130(2):435–52.

    CAS  PubMed  Article  Google Scholar 

  26. 26.

    Zhao C, Chen W, Yang L, et al. PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun. 2006;350(2):385–91.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  27. 27.

    Puche JE, Lee YA, Jiao J, et al. A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice. Hepatology. 2013;57(1):339–50.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  28. 28.

    Pinzani M, Milani S, Herbst H, et al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol. 1996;148(3):785–800.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Nagatsuma K, Hano H, Murakami K, et al. Hepatic stellate cells that coexpress LRAT and CRBP-1 partially contribute to portal fibrogenesis in patients with human viral hepatitis. Liver Int. 2014;34(2):243–52.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Hetherington AM, Sawyez CG, Zilberman E, et al. Differential lipotoxic effects of palmitate and oleate in activated human hepatic stellate cells and epithelial hepatoma cells. Cell Physiol Biochem. 2016;39(4):1648–62.

    CAS  PubMed  Article  Google Scholar 

  31. 31.

    El Taghdouini A, Najimi M, Sancho-Bru P, et al. In vitro reversion of activated primary human hepatic stellate cells. Fibrogenesis Tissue Repair. 2015;8:14.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  32. 32.

    Pirazzi C, Valenti L, Motta BM, et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet. 2014;23(15):4077–85.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Glassner A, Eisenhardt M, Kramer B, et al. NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner. Lab Invest. 2012;92(7):967–77.

    PubMed  Article  CAS  Google Scholar 

  34. 34.

    Friedman SL, Roll FJ. Isolation and culture of hepatic lipocytes, Kupffer cells, and sinusoidal endothelial cells by density gradient centrifugation with Stractan. Anal Biochem. 1987;161(1):207–18.

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Demoise CF, Galambos JT, Falek A. Tisstue culture of adult human liver. Gastroenterology. 1971;60(3):390–9.

    CAS  PubMed  Google Scholar 

  36. 36.

    Galambos JT, Hollingsworth MA Jr, Falek A, et al. The rate of synthesis of glycosaminoglycans and collagen by fibroblasts cultured from adult human liver biopsies. J Clin Invest. 1977;60(1):107–14.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  37. 37.

    Voss B, Rauterberg J, Pott G, et al. Nonparenchymal cells cultivated from explants of fibrotic liver resemble endothelial and smooth muscle cells from blood vessel walls. Hepatology. 1982;2(1):19–28.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Win KM, Charlotte F, Mallat A, et al. Mitogenic effect of transforming growth factor-beta 1 on human Ito cells in culture: evidence for mediation by endogenous platelet-derived growth factor. Hepatology. 1993;18(1):137–45.

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Blazejewski S, Preaux AM, Mallat A, et al. Human myofibroblast-like cells obtained by outgrowth are representative of the fibrogenic cells in the liver. Hepatology. 1995;22(3):788–97.

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    Mallat A, Preaux AM, Blazejewski S, et al. Effect of simvastatin, an inhibitor of hydroxy-methylglutaryl coenzyme A reductase, on the growth of human Ito cells. Hepatology. 1994;20(6):1589–94.

    CAS  PubMed  Article  Google Scholar 

  41. 41.

    Tao J, Mallat A, Gallois C, et al. Biological effects of C-type natriuretic peptide in human myofibroblastic hepatic stellate cells. J Biol Chem. 1999;274(34):23761–9.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Levy MT, McCaughan GW, Abbott CA, et al. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology. 1999;29(6):1768–78.

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Davis BH, Coll D, Beno DW. Retinoic acid suppresses the response to platelet-derived growth factor in human hepatic Ito-cell-like myofibroblasts: a post-receptor mechanism independent of raf/fos/jun/egr activation. Biochem J. 1993;294(Pt 3):785–91.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. 44.

    Pinzani M, Failli P, Ruocco C, et al. Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest. 1992;90(2):642–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Marra F, Valente AJ, Pinzani M, et al. Cultured human liver fat-storing cells produce monocyte chemotactic protein-1. Regulation by proinflammatory cytokines. J Clin Invest. 1993;92(4):1674–80.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Alpini G, Phillips JO, Vroman B, et al. Recent advances in the isolation of liver cells. Hepatology. 1994;20(2):494–514.

    CAS  PubMed  Article  Google Scholar 

  47. 47.

    Casini A, Pinzani M, Milani S, et al. Regulation of extracellular matrix synthesis by transforming growth factor beta 1 in human fat-storing cells. Gastroenterology. 1993;105(1):245–53.

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Pinzani M, Gentilini A, Caligiuri A, et al. Transforming growth factor-beta 1 regulates platelet-derived growth factor receptor beta subunit in human liver fat-storing cells. Hepatology. 1995;21(1):232–9.

    CAS  PubMed  Google Scholar 

  49. 49.

    Kegel V, Deharde D, Pfeiffer E, et al. Protocol for isolation of primary human hepatocytes and corresponding major populations of non-parenchymal liver cells. J Vis Exp. 2016;109:e53069.

    Google Scholar 

  50. 50.

    Pfeiffer E, Kegel V, Zeilinger K, et al. Featured article: isolation, characterization, and cultivation of human hepatocytes and non-parenchymal liver cells. Exp Biol Med (Maywood). 2015;240(5):645–56.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. 51.

    Geerts A, Niki T, Hellemans K, et al. Purification of rat hepatic stellate cells by side scatter-activated cell sorting. Hepatology. 1998;27(2):590–8.

    CAS  PubMed  Article  Google Scholar 

  52. 52.

    Matsuura T, Nagamori S, Fujise K, et al. Retinol transport in cultured fat-storing cells of rat liver. Quantitative analysis by anchored cell analysis and sorting system. Lab Invest. 1989;61(1):107–15.

    CAS  PubMed  Google Scholar 

  53. 53.

    Verrill C, Davies J, Millward-Sadler H, et al. Organotypic liver culture in a fluid-air interface using slices of neonatal rat and adult human tissue—a model of fibrosis in vitro. J Pharmacol Toxicol Methods. 2002;48(2):103–10.

    CAS  PubMed  Article  Google Scholar 

  54. 54.

    van de Bovenkamp M, Groothuis GM, Meijer DK, et al. Human liver slices as an in vitro model to study toxicity-induced hepatic stellate cell activation in a multicellular milieu. Chem Biol Interact. 2006;162(1):62–9.

    PubMed  Article  CAS  Google Scholar 

  55. 55.

    Guyot C, Combe C, Balabaud C, et al. Fibrogenic cell fate during fibrotic tissue remodelling observed in rat and human cultured liver slices. J Hepatol. 2007;46(1):142–50.

    CAS  PubMed  Article  Google Scholar 

  56. 56.

    Guyot C, Lepreux S, Combe C, et al. Fibrogenic cell phenotype modifications during remodelling of normal and pathological human liver in cultured slices. Liver Int. 2010;30(10):1529–40.

    PubMed  Article  Google Scholar 

  57. 57.

    Dong W, Lu A, Zhao J, et al. An efficient and simple co-culture method for isolating primary human hepatic cells: potential application for tumor microenvironment research. Oncol Rep. 2016;36(4):2126–34.

    CAS  PubMed  Article  Google Scholar 

  58. 58.

    Yokoi Y, Namihisa T, Kuroda H, et al. Immunocytochemical detection of desmin in fat-storing cells (Ito cells). Hepatology. 1984;4(4):709–14.

    CAS  PubMed  Article  Google Scholar 

  59. 59.

    Gard AL, White FP, Dutton GR. Extra-neural glial fibrillary acidic protein (GFAP) immunoreactivity in perisinusoidal stellate cells of rat liver. J Neuroimmunol. 1985;8(4–6):359–75.

    CAS  PubMed  Article  Google Scholar 

  60. 60.

    Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis. 2001;21(3):311–35.

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    Cassiman D, Roskams T. Beauty is in the eye of the beholder: emerging concepts and pitfalls in hepatic stellate cell research. J Hepatol. 2002;37(4):527–35.

    PubMed  Article  Google Scholar 

  62. 62.

    Minato Y, Hasumura Y, Takeuchi J. The role of fat-storing cells in Disse space fibrogenesis in alcoholic liver disease. Hepatology. 1983;3(4):559–66.

    CAS  PubMed  Article  Google Scholar 

  63. 63.

    Blaner WS, O’Byrne SM, Wongsiriroj N, et al. Hepatic stellate cell lipid droplets: a specialized lipid droplet for retinoid storage. Biochim Biophys Acta. 2009;1791(6):467–73.

    CAS  PubMed  Article  Google Scholar 

  64. 64.

    Motoyama H, Komiya T, le Thuy TT, et al. Cytoglobin is expressed in hepatic stellate cells, but not in myofibroblasts, in normal and fibrotic human liver. Lab Invest. 2014;94(2):192–207.

    CAS  PubMed  Article  Google Scholar 

  65. 65.

    Sztark F, Dubroca J, Latry P, et al. Perisinusoidal cells in patients with normal liver histology: a morphometric study. J Hepatol. 1986;2(3):358–69.

    CAS  PubMed  Article  Google Scholar 

  66. 66.

    Schmitt-Graff A, Kruger S, Bochard F, et al. Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am J Pathol. 1991;138(5):1233–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. 67.

    Nouchi T, Tanaka Y, Tsukada T, et al. Appearance of alpha-smooth-muscle-actin-positive cells in hepatic fibrosis. Liver. 1991;11(2):100–5.

    CAS  PubMed  Article  Google Scholar 

  68. 68.

    Enzan H, Himeno H, Iwamura S, et al. Immunohistochemical identification of Ito cells and their myofibroblastic transformation in adult human liver. Virchows Arch. 1994;424(3):249–56.

    CAS  PubMed  Article  Google Scholar 

  69. 69.

    Cassiman D, Libbrecht L, Desmet V, et al. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol. 2002;36(2):200–9.

    PubMed  Article  Google Scholar 

  70. 70.

    Van Rossen E, Vander Borght S, van Grunsven LA, et al. Vinculin and cellular retinol-binding protein-1 are markers for quiescent and activated hepatic stellate cells in formalin-fixed paraffin embedded human liver. Histochem Cell Biol. 2009;131(3):313–25.

    PubMed  Article  CAS  Google Scholar 

  71. 71.

    Cassiman D, Roskams T, van Pelt J, et al. Alpha B-crystallin expression in human and rat hepatic stellate cells. J Hepatol. 2001;35(2):200–7.

    CAS  PubMed  Article  Google Scholar 

  72. 72.

    Yamaoka K, Nouchi T, Marumo F, et al. Alpha-smooth-muscle actin expression in normal and fibrotic human livers. Dig Dis Sci. 1993;38(8):1473–9.

    CAS  PubMed  Article  Google Scholar 

  73. 73.

    Nagatsuma K, Hayashi Y, Hano H, et al. Lecithin: retinol acyltransferase protein is distributed in both hepatic stellate cells and endothelial cells of normal rodent and human liver. Liver Int. 2009;29(1):47–54.

    CAS  PubMed  Article  Google Scholar 

  74. 74.

    Bioulac-Sage P, Lafon ME, Saric J, et al. Nerves and perisinusoidal cells in human liver. J Hepatol. 1990;10(1):105–12.

    CAS  PubMed  Article  Google Scholar 

  75. 75.

    Cassiman D, Denef C, Desmet VJ, et al. Human and rat hepatic stellate cells express neurotrophins and neurotrophin receptors. Hepatology. 2001;33(1):148–58.

    CAS  PubMed  Article  Google Scholar 

  76. 76.

    Oben JA, Roskams T, Yang S, et al. Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut. 2004;53(3):438–45.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  77. 77.

    Roskams T, Cassiman D, De Vos R, et al. Neuroregulation of the neuroendocrine compartment of the liver. Anat Rec A Discov Mol Cell Evol Biol. 2004;280(1):910–23.

    PubMed  Article  CAS  Google Scholar 

  78. 78.

    Niki T, Pekny M, Hellemans K, et al. Class VI intermediate filament protein nestin is induced during activation of rat hepatic stellate cells. Hepatology. 1999;29(2):520–7.

    CAS  PubMed  Article  Google Scholar 

  79. 79.

    Trim N, Morgan S, Evans M, et al. Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation. Am J Pathol. 2000;156(4):1235–43.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  80. 80.

    Donovan MJ, Miranda RC, Kraemer R, et al. Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. Am J Pathol. 1995;147(2):309–24.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. 81.

    Nakatani K, Seki S, Kawada N, et al. Expression of neural cell adhesion molecule (N-CAM) in perisinusoidal stellate cells of the human liver. Cell Tissue Res. 1996;283(1):159–65.

    CAS  PubMed  Article  Google Scholar 

  82. 82.

    Kato M, Kato K, Goodman DS. Immunocytochemical studies on the localization of plasma and of cellular retinol-binding proteins and of transthyretin (prealbumin) in rat liver and kidney. J Cell Biol. 1984;98(5):1696–704.

    CAS  PubMed  Article  Google Scholar 

  83. 83.

    Kristensen DB, Kawada N, Imamura K, et al. Proteome analysis of rat hepatic stellate cells. Hepatology. 2000;32(2):268–77.

    CAS  PubMed  Article  Google Scholar 

  84. 84.

    Asahina K, Kawada N, Kristensen DB, et al. Characterization of human stellate cell activation-associated protein and its expression in human liver. Biochim Biophys Acta. 2002;1577(3):471–5.

    CAS  PubMed  Article  Google Scholar 

  85. 85.

    Kawada N, Kristensen DB, Asahina K, et al. Characterization of a stellate cell activation-associated protein (STAP) with peroxidase activity found in rat hepatic stellate cells. J Biol Chem. 2001;276(27):25318–23.

    CAS  PubMed  Article  Google Scholar 

  86. 86.

    Dudas J, Mansuroglu T, Batusic D, et al. Thy-1 is expressed in myofibroblasts but not found in hepatic stellate cells following liver injury. Histochem Cell Biol. 2009;131(1):115–27.

    CAS  PubMed  Article  Google Scholar 

  87. 87.

    Wilhelm A, Aldridge V, Haldar D, et al. CD248/endosialin critically regulates hepatic stellate cell proliferation during chronic liver injury via a PDGF-regulated mechanism. Gut. 2016;65(7):1175–85.

    CAS  PubMed  Article  Google Scholar 

  88. 88.

    Stone LC, Thorne LS, Weston CJ, et al. Cytoglobin expression in the hepatic stellate cell line HSC-T6 is regulated by extracellular matrix proteins dependent on FAK-signalling. Fibrogenesis Tissue Repair. 2015;8:15.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  89. 89.

    De Minicis S, Seki E, Uchinami H, et al. Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology. 2007;132(5):1937–46.

    PubMed  Article  CAS  Google Scholar 

  90. 90.

    Levy MT, McCaughan GW, Marinos G, et al. Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. Liver. 2002;22(2):93–101.

    CAS  PubMed  Article  Google Scholar 

  91. 91.

    Pinzani M, Milani S, Grappone C, et al. Expression of platelet-derived growth factor in a model of acute liver injury. Hepatology. 1994;19(3):701–7.

    CAS  PubMed  Article  Google Scholar 

  92. 92.

    Pinzani M. PDGF and signal transduction in hepatic stellate cells. Front Biosci. 2002;7:d1720–6.

    CAS  PubMed  Article  Google Scholar 

  93. 93.

    Heldin P, Pertoft H, Nordlinder H, et al. Differential expression of platelet-derived growth factor alpha- and beta- receptors on fat-storing cells and endothelial cells of rat liver. Exp Cell Res. 1991;193(2):364–9.

    CAS  PubMed  Article  Google Scholar 

  94. 94.

    Wong L, Yamasaki G, Johnson RJ, et al. Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest. 1994;94(4):1563–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  95. 95.

    Henderson NC, Arnold TD, Katamura Y, et al. Targeting of alpha-v integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013;19(12):1617–24.

    CAS  PubMed  Article  Google Scholar 

  96. 96.

    Yu MC, Chen CH, Liang X, et al. Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology. 2004;40(6):1312–21.

    CAS  PubMed  Article  Google Scholar 

  97. 97.

    Cassiman D, van Pelt J, De Vos R, et al. Synaptophysin: a novel marker for human and rat hepatic stellate cells. Am J Pathol. 1999;155(6):1831–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  98. 98.

    Elrick LJ, Leel V, Blaylock MG, et al. Generation of a monoclonal human single chain antibody fragment to hepatic stellate cells–a potential mechanism for targeting liver anti-fibrotic therapeutics. J Hepatol. 2005;42(6):888–96.

    CAS  PubMed  Article  Google Scholar 

  99. 99.

    Herrmann J, Gressner AM, Weiskirchen R. Immortal hepatic stellate cell lines: useful tools to study hepatic stellate cell biology and function? J Cell Mol Med. 2007;11(4):704–22.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  100. 100.

    Murakami K, Abe T, Miyazawa M, et al. Establishment of a new human cell line, LI90, exhibiting characteristics of hepatic Ito (fat-storing) cells. Lab Invest. 1995;72(6):731–9.

    CAS  PubMed  Google Scholar 

  101. 101.

    Migita K, Maeda Y, Abiru S, Nakamura M, et al. Immunosuppressant FK506 inhibits matrix metalloproteinase-9 induction in TNF-alpha-stimulated human hepatic stellate cells. Life Sci. 2006;78(21):2510–5.

    CAS  PubMed  Article  Google Scholar 

  102. 102.

    Ikeda N, Murata S, Maruyama T, et al. Platelet-derived adenosine 5′-triphosphate suppresses activation of human hepatic stellate cell: in vitro study. Hepatol Res. 2012;42(1):91–102.

    PubMed  Article  Google Scholar 

  103. 103.

    Watanabe T, Shibata N, Westerman KA, et al. Establishment of immortalized human hepatic stellate scavenger cells to develop bioartificial livers. Transplantation. 2003;75(11):1873–80.

    CAS  PubMed  Article  Google Scholar 

  104. 104.

    Shibata N, Watanabe T, Okitsu T, et al. Establishment of an immortalized human hepatic stellate cell line to develop antifibrotic therapies. Cell Transplant. 2003;12(5):499–507.

    PubMed  Article  Google Scholar 

  105. 105.

    Schnabl B, Choi YH, Olsen JC, et al. Immortal activated human hepatic stellate cells generated by ectopic telomerase expression. Lab Invest. 2002;82(3):323–33.

    CAS  PubMed  Article  Google Scholar 

  106. 106.

    Schnabl B, Purbeck CA, Choi YH, et al. Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology. 2003;37(3):653–64.

    CAS  PubMed  Article  Google Scholar 

  107. 107.

    Xu L, Hui AY, Albanis E, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut. 2005;54(1):142–51.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  108. 108.

    Rashid ST, Humphries JD, Byron A, et al. Proteomic analysis of extracellular matrix from the hepatic stellate cell line LX-2 identifies CYR61 and Wnt-5a as novel constituents of fibrotic liver. J Proteome Res. 2012;11(8):4052–64.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  109. 109.

    Ding N, Hah N, Yu RT, et al. BRD4 is a novel therapeutic target for liver fibrosis. Proc Natl Acad Sci USA. 2015;112(51):15713–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  110. 110.

    Ajat M, Molenaar M, Brouwers JF, et al. Hepatic stellate cells retain the capacity to synthesize retinyl esters and to store neutral lipids in small lipid droplets in the absence of LRAT. Biochim Biophys Acta. 2017;1862(2):176–87.

    CAS  PubMed  Article  Google Scholar 

  111. 111.

    Weill FX, Blazejewski S, Blanc JF, et al. Characterization of a new human liver myofibroblast cell line: transcriptional regulation of plasminogen activator inhibitor type I by transforming growth factor beta 1. Lab Invest. 1997;77(1):63–70.

    CAS  PubMed  Google Scholar 

  112. 112.

    Pan X, Wang Y, Yu X, et al. Establishment and characterization of an immortalized human hepatic stellate cell line for applications in co-culturing with immortalized human hepatocytes. Int J Med Sci. 2015;12(3):248–55.

    PubMed  PubMed Central  Article  Google Scholar 

  113. 113.

    Blouin A, Bolender RP, Weibel ER. Distribution of organelles and membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma. A stereological study. J Cell Biol. 1977;72(2):441–55.

    CAS  PubMed  Article  Google Scholar 

  114. 114.

    Kisseleva T, Cong M, Paik Y, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci USA. 2012;109(24):9448–53.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  115. 115.

    Friedman SL. Fibrogenic cell reversion underlies fibrosis regression in liver. Proc Natl Acad Sci USA. 2012;109(24):9230–1.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  116. 116.

    Hardy T, Mann DA. Epigenetics in liver disease: from biology to therapeutics. Gut. 2016;65(11):1895–905.

    PubMed  PubMed Central  Article  Google Scholar 

  117. 117.

    Hazra S, Xiong S, Wang J, et al. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem. 2004;279(12):11392–401.

    CAS  PubMed  Article  Google Scholar 

  118. 118.

    Knight V, Tchongue J, Lourensz D, et al. Protease-activated receptor 2 promotes experimental liver fibrosis in mice and activates human hepatic stellate cells. Hepatology. 2012;55(3):879–87.

    CAS  PubMed  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to David Allen Brenner.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Shang, L., Hosseini, M., Liu, X. et al. Human hepatic stellate cell isolation and characterization. J Gastroenterol 53, 6–17 (2018).

Download citation


  • Human hepatic stellate cells
  • Human HSC isolation
  • Human HSC markers
  • Human hepatic stellate cell lines